• About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng
Menu
  • About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng

A New Therapeutic Vaccine Successfully Developed Against Rabies

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, March 16, 2015 /PRNewswire/  Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine...
Continue Reading

Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Collaboration on New Vaccine Against Ebola Virus

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Dec. 14, 2015 /PRNewswire/  Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced that Yisheng...
Continue Reading

Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Jan. 4, 2016 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of vaccine products, today announced positive topline results...
Continue Reading

Yisheng Biopharma and the United States Army Medical Research Institute of Infectious Diseases Announce Positive Animal Results of Vaccine Against Ebola Virus

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING and FORT DETRICK, Md., July 14, 2016 /PRNewswire/  Yisheng Biopharma Co., Ltd.  (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of biological vaccines...
Continue Reading

The US FDA Granted Orphan Drug Designation to Yisheng Biopharma’s Biological Product for Hepatocellular Carcinoma

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Oct. 24, 2016 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced that...
Continue Reading

Yisheng Biopharma Announces Completion of Phase I Clinical Study of a Novel Hepatitis B Vaccine with PIKA Adjuvant

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Nov. 21, 2016 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological therapeutics, today announced the completion of...
Continue Reading

US FDA Grants Orphan Drug Designation to Yisheng Biopharma’s PIKA Rabies Vaccine

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Jan. 4, 2017 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced...
Continue Reading

Yisheng Biopharma to Present at BioPharma Asia Convention 2017 in Singapore

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, March 15, 2017 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-therapeutic products and vaccines, today announced...
Continue Reading

Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, May 1, 2017 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced...
Continue Reading

Yisheng Biopharma Announces New Breakthrough Results on YS-ON-001 in Multiple Solid Tumor Experiments

  • June 25, 2021
  • wordpress202104
  • Uncategorized
BEIJING, Aug. 30, 2017 /PRNewswire/  Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immuno-oncology products and vaccines, today announced...
Continue Reading

Posts navigation

1 2 Next

Search

Recent Posts

  • YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP
  • YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
  • YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
  • YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
  • A New Therapeutic Vaccine Successfully Developed Against Rabies

Recent Comments

    Archives

    • November 2022
    • September 2022
    • June 2021
    • May 2021
    • February 2021

    Categories

    • 2022
    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Site MapTerms of UsePrivacy

    Contact Info

    YS Biopharma Co., Ltd.

    11 Firstfield Road Suite A
    Gaithersburg, Maryland 20878 USA

    Tel: +1 (301) 208 8823
    Fax: +1 (301) 208 8827

    bjinfo@yishengbio.com

    Copyright © 2021 Yisheng Biopharma. All Rights Reserved.